A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia
Latest Information Update: 15 Apr 2021
At a glance
- Drugs Acamprosate (Primary)
- Indications Drug-induced dyskinesia
- Focus Therapeutic Use
- Sponsors Synchroneuron
- 08 Apr 2021 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015.
- 08 Apr 2021 Status changed from completed to withdrawn prior to enrolment.
- 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.